TScan Therapeutics (TCRX) Enterprise Value (2020 - 2025)
TScan Therapeutics (TCRX) has disclosed Enterprise Value for 6 consecutive years, with -$152.4 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 47.47% to -$152.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$152.4 million, a 47.47% increase, with the full-year FY2025 number at -$152.4 million, up 47.47% from a year prior.
- Enterprise Value was -$152.4 million for Q4 2025 at TScan Therapeutics, up from -$184.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$48.7 million in Q2 2025 to a low of -$297.7 million in Q2 2024.
- A 5-year average of -$173.3 million and a median of -$162.1 million in 2021 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: plummeted 363.93% in 2021, then skyrocketed 83.66% in 2025.
- TScan Therapeutics' Enterprise Value stood at -$161.4 million in 2021, then rose by 25.64% to -$120.0 million in 2022, then crashed by 60.0% to -$192.0 million in 2023, then tumbled by 51.06% to -$290.1 million in 2024, then soared by 47.47% to -$152.4 million in 2025.
- Per Business Quant, the three most recent readings for TCRX's Enterprise Value are -$152.4 million (Q4 2025), -$184.5 million (Q3 2025), and -$48.7 million (Q2 2025).